Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to make repeat radiation safer for cancer patients

NCT ID NCT07528339

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will collect data from 500 Danish cancer patients who need repeat radiation therapy (reirradiation). Researchers will track side effects, tumor control, and survival to build a database that can guide safer treatment in the future. The goal is to help doctors decide when and how to safely give radiation again to patients whose cancer has returned.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
reirradiation (radiation therapy)
What this could lead to
If successful, this registry could help doctors better understand how to safely deliver repeat radiation to cancer patients, potentially expanding treatment options.
What could go wrong
This is an observational registry, not a treatment trial. It will not directly test a new therapy, and results may take years to influence practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Mar 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

No guidelines are provided on the selection of patients for high dose reirradiation. All patients are eligible for the database if treated with reirradiation with the aim of local control.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * High dose reirradiation (reirradiation type I or II or repeat organ irradiation delivered with the aim of local control) Read Danish (for questionnaires + patient information) Life expectancy due to age and co-morbidity of ≥6 months. The general condition must be sufficient to tolerate persistent significant side effects Histological or imaging verified loco-regional recurrence, solitary oligo metastasis or new primary Age ≥18 years Signed informed consent, updated annually Expected follow up physical, by video, by phone or likely contact at a relevant oncological department Available dose plan(s) from primary (and prior) radiotherapy course(s) (with 3D reconstruction of previous plans, available port film, or drawings). Multiple re-treatments are allowed (new inclusion and baseline registration) Exclusion Criteria: * The primary and reirradiation treatments may not be quasi-simultaneous (i.e. the two treatments should be planned independently) Inability to attend full course of radiotherapy Purpose of radiotherapy is ONLY palliation of symptoms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radiotherapy side effect

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.